Based upon the uniquely stated Question Presented in Sequenom, Inc. v. Ariosa Diagnostics, Inc., Supreme Court No. 15-1182, the relevant issue for the biotechnology and pharmaceutical industries is now whether one should participate as an amicus at the current, petition stage, or, whether it is better to first await the certiorari decision (and then, if granted, participate at the merits stage).
The issue is considered in more detail in Patent-Eligibility: Whither Sequenom?
SequenomPatentEligibilityMarch23
Regards,
Hal